Skelaxin Generics May Launch Before July 2005: FDA To Allow Labeling "Carve Out"
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency says ANDA filers Eon and Corepharma may delete protected labeling on food effects covered by King’s method-of-use patent.
You may also be interested in...
King Plans Skelaxin “Authorized” Generic When Metaxalone ANDAs Launch
King will launch an "authorized" generic of Skelaxin (metaxalone) when ANDA versions of the muscle relaxant enter the market
King Plans Skelaxin “Authorized” Generic When Metaxalone ANDAs Launch
King will launch an "authorized" generic of Skelaxin (metaxalone) when ANDA versions of the muscle relaxant enter the market
Mylan To Pay $4 Bil. For King Ahead Of Launch Of Beta Blocker Nebivolol
The company cites King’s 1,200-person sales force as one reason behind the acquisition. King’s cardiovascular marketing experience with the ACE inhibitor Altace will be beneficial as Mylan anticipates approval for its beta blocker nebivolol.